Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvoglustat + rhGAA in Pompe Disease
NCT01380743Phase 2Completed
- Sponsor
- Amicus Therapeutics
- Start
- Oct 2011
- Primary completion
- Jan 2013
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 2, open-label trial of duvoglustat in Pompe disease (4 cohorts), sponsored by Amicus Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events, Maximum Measured Plasma Concentration at 7 days and 3 more. Started Oct 2011; status: completed.
02
Drugs
duvoglustat
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT01380743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01380743.